CSX Corporation vs Recursion Pharmaceuticals Inc — how do they compare? CSX Corporation trades at $50.06 (market cap $92.55B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.81B). The key difference: CSX Corporation is far larger — about 51.1× Recursion Pharmaceuticals Inc's market cap, and CSX Corporation pays a 1.12% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CSX | RXRX | |
|---|---|---|
Market Cap | $92.55B | $1.81B |
Sector | Industrials | Health |
52-Week High | $53.21 | $6.79 |
52-Week Low | $32.05 | $2.84 |
Enterprise Value | $110.52B | $1.33B |
Dividend Yield | 1.12% | — |
Trailing returns across standard periods
Latest headlines on both assets
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →